Bristol/Exelixis Detail Survival Benefit For Opdivo/Cabometyx In Renal Cancer

 
• By Joseph Haas
  
Kidney
BMS and Exelixis hope they'll have the best combo data for first-line RCC
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D